X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
NOVARTIS Announces Quarterly Results (4QFY18); Net Profit Up 809.6%

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NOVARTIS Announces Quarterly Results (4QFY18); Net Profit Up 809.6%
Fri, 20 Jul

NOVARTIS has announced its results for the quarter ended March 2018. Here is a detailed performance review of the same:

NOVARTIS Quarterly Financials

No. of Mths
Qtr. Ending
3
Mar-17*
3
Dec-17*
3
Mar-18*
QoQ ChangeYoY Change
Net SalesRs m1,4551,5611,253-19.7%-13.9%
Other incomeRs m1481451,096658.5%640.0%
TurnoverRs m1,6031,7062,34937.7%46.6%
ExpensesRs m1,5141,4431,4722.0%-2.8%
Gross profitRs m-59118-219-285.3%
DepreciationRs m135618.5%-52.2%
InterestRs m43511506.3%1217.9%
Profit before taxRs m72254819222.4%1044.1%
TaxRs m4367555731.3%1204.7%
Profit after taxRs m2918726541.2%809.6%
Gross profit margin%-4.17.6-17.5
Effective tax rate%59.426.267.7
Net profit margin%1.811.011.3
* Results Consolidated
Interim results exclude extraordinary / exceptional items
Source: Company Reports, Regulatory Filings, Equitymaster


Year-on-Year Performance:
  • The company's operating income during the quarter fell 13.9% on a year-on-year (YoY) basis. The expenses were down by 2.8% YoY during the same period.
  • The company's operating profit increased by 269.9% YoY during the quarter. Consequently, operating profit margins witnessed a decline and stood at 17.5% in 4QFY18 as against 4.1% in 4QFY17.
  • Depreciation charges and finance costs declined by 52.2% YoY and 1217.9% YoY, respectively.
  • Other income increased by 640.0% YoY during the quarter.
  • Net profit for the quarter increased by 809.6% YoY. Net profit margins during the quarter increased from 1.8% in 4QFY17 to 11.3% in 4QFY18.
Quarter-on-Quarter Performance:
  • The company's operating income during the quarter fell 19.7% on a quarter-on-quarter (QoQ) basis. The expenses were up by 2.0% QoQ during the same period.
  • The company's operating profit declined by 285.3% QoQ during the quarter. Consequently, operating profit margins witnessed a decline and stood at 17.5% in 4QFY18 as against 7.6% in 3QFY17.
  • Net profit for the quarter increased by 41.2% QoQ, while net profit margins same from 11.0% in 3QFY17 to 11.3% in 4QFY18.

To see how NOVARTIS has performed over the last eight quarters, please visit here.

NOVARTIS Share Price Performance

Over the last one year, NOVARTIS share price has moved up from Rs 637.8 to Rs 625.0, registering a Loss of Rs -12.9 or around 2.0%.

Meanwhile, the S&P BSE HEALTHCARE Index is trading at Rs 13,620.9 (up 0.8%). Over the last one year it has moved down from 14,918.1 to 13,620.9, a gain of -1,297.3 points (down 8.7%).

Overall, the S&P BSE SENSEX is up 0.4% over the year.

Current Valuations

At the current price of Rs 625.0, the price to earnings (P/E) ratio of NOVARTIS stands at 267.5 times its trailing twelve months earnings, while its price to book value (P/BV) ratio stands at 28.6 times.

Equitymaster requests your view! Post a comment on "NOVARTIS Announces Quarterly Results (4QFY18); Net Profit Up 809.6%". Click here!

  

Related Views on News

NOVARTIS Announces Quarterly Results (4QFY19); Net Profit Down 26.2% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, NOVARTIS has posted a net profit of Rs 195 m (down 26.2% YoY). Sales on the other hand came in at Rs 1 bn (down 11.9% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

NOVARTIS Announces Quarterly Results (3QFY19); Net Profit Down 31.3% (Quarterly Result Update)

Feb 13, 2019 | Updated on Feb 13, 2019

For the quarter ended December 2018, NOVARTIS has posted a net profit of Rs 129 m (down 31.3% YoY). Sales on the other hand came in at Rs 1 bn (down 13.1% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

These 3 Smallcap Stocks are Set to Make the Most of Smallcap Rebound(Profit Hunter)

Jul 9, 2019

As the sense of normalcy returns to the markets, the rebound in the quality smallcaps could be huge.

2 Stocks from Super Investor Sanjay Bakshi's Portfolio You Can Bet On...(The 5 Minute Wrapup)

Jul 12, 2019

Despite the current fear prevailing in the markets, both these stocks have the potential to deliver in 4-5 years.

After Disappointing Budget, Here's a Document that Concerns Largecap and Smallcap Investors(The 5 Minute Wrapup)

Jul 8, 2019

A new 'definition' of the stock universe that triggered the smallcap sell-off is back with the latest list...

Union Budget 2019-2020: More Style Over Substance(The 5 Minute Wrapup)

Jul 5, 2019

Did the Union Budget announce measures to stimulate the economy and bolster corporate earnings growth?

Here's What to Do with Falling Small Cap Stocks(Profit Hunter)

Jul 10, 2019

There are some great buying opportunities in the market right now - and the small cap space is your best bet.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

NOVARTIS SHARE PRICE


Jul 18, 2019 (Close)

TRACK NOVARTIS

  • Track your investment in NOVARTIS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

NOVARTIS - STRIDES PHARMA SCIENCE COMPARISON

COMPARE NOVARTIS WITH

MARKET STATS